- Home
- RELY vs TARS Comparison
RELY vs TARS Comparison
Compare RELY & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RELY | TARS |
|---|---|---|
| Founded | 2011 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.8B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RELY | TARS |
|---|---|---|
| Price | $15.56 | $67.67 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 6 |
| Target Price | $24.13 | ★ $89.00 |
| AVG Volume (30 Days) | ★ 4.4M | 534.2K |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 263.16 | 48.21 |
| EPS | ★ 0.31 | N/A |
| Revenue | ★ $1,635,147,000.00 | $451,360,000.00 |
| Revenue This Year | $21.82 | $55.67 |
| Revenue Next Year | $19.08 | $30.64 |
| P/E Ratio | $50.34 | ★ N/A |
| Revenue Growth | 29.37 | ★ 146.71 |
| 52 Week Low | $12.08 | $38.51 |
| 52 Week High | $24.63 | $85.25 |
Technical Indicators
Market Signals| Indicator | RELY | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 48.00 | 41.59 |
| Support Level | $14.72 | $65.62 |
| Resistance Level | $15.77 | $67.70 |
| Average True Range (ATR) | 0.65 | 2.45 |
| MACD | -0.27 | -0.71 |
| Stochastic Oscillator | 14.45 | 6.82 |
Price Performance
Historical ComparisonAbout RELY Remitly Global Inc.
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. The company's revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.